ASX:CSLCSL Stock Price, Forecast & News

A$307.61

+2.39 (+0.78 %)

(As of 05/12/2020)

Add

Compare

Today's Range

A$302.31

Now: A$307.61▼

A$308.00

50-Day Range

A$298.76

MA: A$312.55▼

A$329.00

52-Week Range

A$200.37

Now: A$307.61▼

A$342.75

Volume869,289 shs

Average Volume900,202 shs

Market Capitalization$139.62 billion

P/E Ratio69.64

Dividend Yield0.97%

BetaN/A

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. It also operates approximately 140 plasma collection centers. In addition, this segment conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and developsinfluenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for CSL.

3.0 Community Rank

Outperform Votes
CSL has received 203 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
CSL has received 140 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
CSL has received 59.18% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about CSL and other stocks. Vote “Outperform” if you believe CSL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CSL will underperform the S&P 500 over the long term. You may vote once every thirty days.

2.5 Dividend Strength

Dividend Leadership
CSL is a leading dividend payer. It pays a dividend yield of 0.97%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
CSL does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of CSL is 66.33 %. This payout ratio is at a healthy, sustainable level, below 75%.

3.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CSL insiders have bought more of their company's stock than they have sold. Specifically, they have bought A$99,487.00 in company stock and sold A$0.00 in company stock.

0.0 Earnings and Valuation

Earnings Growth
Earnings for CSL are expected to decrease by -100.00% in the coming year, from A$4.90 to A$0.00 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of CSL is 69.64, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.40.
Price to Earnings Ratio vs. Sector
The P/E ratio of CSL is 69.64, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.10.
Price to Earnings Growth Ratio
CSL has a PEG Ratio of 2.43. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
CSL has a P/B Ratio of 22.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.70 out of 5 stars

Industry, Sector and Symbol

Stock Exchange ASX

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

Current SymbolASX:CSL

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.csl.com.au

Phone+61-3-93891911

Debt

Debt-to-Equity Ratio92.27

Current Ratio2.19

Quick Ratio1.00

Price-To-Earnings

Trailing P/E Ratio69.64

Forward P/E Ratio62.79

P/E Growth2.43

Sales & Book Value

Annual Sales$8.94 billion

Price / Sales15.61

Cash FlowA$1.48 per share

Price / Cash Flow207.70

Book ValueA$13.40 per share

Price / Book22.96

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

EmployeesN/A

Outstanding Shares453,881,984

Market Cap$139.62 billion

Next Earnings DateN/A

OptionableOptionable

Receive CSL News and Ratings via Email

Sign-up to receive the latest news and ratings for CSL and its competitors with MarketBeat's FREE daily newsletter.

CSL (ASX:CSL) Frequently Asked Questions

How has CSL's stock been impacted by COVID-19 (Coronavirus)?

CSL's stock was trading at A$303.81 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CSL stock has increased by 1.3% and is now trading at A$307.61. View which stocks have been most impacted by Coronavirus.

How were CSL's earnings last quarter?

CSL Limited (ASX:CSL) released its quarterly earnings data on Wednesday, August, 14th. The company reported $4.24 EPS for the quarter, topping analysts' consensus estimates of $4.22 by $0.01. View CSL's earnings history.

How often does CSL pay dividends? What is the dividend yield for CSL?

CSL declared a Interim dividend on Thursday, February 13th. Stockholders of record on Thursday, April 9th will be given a dividend of 1.416 per share on Thursday, April 9th. This represents a yield of 0.43%. The ex-dividend date is Wednesday, March 11th. This is a boost from CSL's previous Interim dividend of A$1.20. View CSL's dividend history.

Has CSL been receiving favorable news coverage?

News stories about CSL stock have trended very negative recently, according to InfoTrie. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. CSL earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news aboutCSL.

Who are some of CSL's key competitors?

Some companies that are related to CSL include MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (MOR), MorphoSys (MOR), MorphoSys (MOR), Vir Biotechnology (VIR), BTG (BTG), Abcam (ABC), Cronos Group (CRON), Kodiak Sciences (KOD), Viela Bio (VIE), Genus (GNS), Mesoblast (MSB), Polynovo (PNV), NGM Biopharmaceuticals (NGM), Concordia International (CXR) and Clinuvel Pharmaceuticals (CUV). View all competitors.

What other stocks do shareholders of CSL own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CSL investors own include BHP Group (BHP), Commonwealth Bank of Australia (CBA), Cochlear (COH), RESMED/IDR UNRESTR (RMD), Woodside Petroleum (WPL), Altium (ALU), Afterpay Touch Group (APT), Appen (APX), REA Group (REA) and Telstra (TLS).

Who are CSL's key executives?

CSL's management team includes the following people:

Mr. Paul R. Perreault, MD, CEO & Exec. Director (Age 62)
Mr. David Mark Lamont ACA, BCom, Chief Financial Officer (Age 53)
Dr. Robert Andrew Cuthbertson, Chief Scientific Officer & Director of R&D and Director (Age 64)
Mr. Gregory Boss BS(Hons), J.D., Exec. VP of Legal & Group Gen. Counsel (Age 58)
Ms. Elizabeth Walker, Exec. VP & Chief HR Officer (Age 49)

What is CSL's stock symbol?

CSL trades on the ASX under the ticker symbol "CSL."

What is CSL's stock price today?

One share of CSL stock can currently be purchased for approximately A$307.61.

How big of a company is CSL?

CSL has a market capitalization of $139.62 billion and generates $8.94 billion in revenue each year.

What is CSL's official website?

The official website for CSL is www.csl.com.au.

How can I contact CSL?

CSL's mailing address is 45 Poplar Road,, Parkville, MELBOURNE, VIC 3052, Australia. The company can be reached via phone at +61-3-93891911.

This page was last updated on 5/29/2020 by MarketBeat.com Staff